Shareholder Alert: Ademi & O'Reilly, LLP Investigates whether Portola Pharmaceuticals, Inc. has obtained a Fair Price in its...

MILWAUKEE, May 5, 2020 /PRNewswire/ -- Ademi & O'Reilly, LLP is investigating Portola (Nasdaq: PTLA) for possible breaches of fiduciary duty and other violations of the law in connection with the sale to Alexion.

Click here to learn how to join the action: http://ademilaw.com/case/portola-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995.  There is no cost or obligation to you.

Ademi & O'Reilly, LLP alleges Portola's financial outlook is improving and yet shareholders will receive only $18 per share in cash. The merger agreement unreasonably limits competing bids for Portola by prohibiting solicitation of further bids, and imposing a termination penalty if Portola accepts a superior bid. Portola insiders will receive millions of dollars as part of change of control arrangements. We are investigating the conduct of Portola's board of directors, and whether they are (i) fulfilling their fiduciary duties to all shareholders, and (ii) obtaining a fair and reasonable price for Portola.

If you own common stock in Portola and wish to obtain additional information, please contact Guri Ademi either at [e-mail] or toll-free: 866-264-3995, or http://ademilaw.com/case/portola-pharmaceuticals-inc.                       

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi & O'Reilly, LLP
Guri Ademi
Toll Free: [phone]
Fax: [phone]

 

View original content:http://www.prnewswire.com/news-releases/shareholder-alert-ademi--oreilly-llp-investigates-whether-portola-pharmaceuticals-inc--has-obtained-a-fair-price-in-its-sale-to-alexion-pharmaceuticals-inc-301053034.html

SOURCE Ademi & O'Reilly, LLP

Copyright 2020 PR Newswire